Título : Hereditary Hemorrhagic Telangiectasia in Uruguay: Epidemiologic and clinical features of the evaluated population.
Autor(es) : Criscuolo, Zelika
Chiesa, Camila
Losada, Germán
Marsiglia, Bruno
Matta, Leandro
Nogara, Renata
Pereira, Hernán
Rodriguez, Sebastián
Mezzano, Rossana
Ruiz, Santiago
Fecha de publicación : 21-ago-2025
Tipo de publicación: Preprint
Areas del conocimiento : Ciencias Médicas y de la Salud
Medicina Clínica
Sistemas Cardíaco y Cardiovascular
Otros descriptores : Hereditary Hemorrhagic Telangiectasia
Epistaxis
Arteriovenous Malformation
Rare Diseases
Epidemiology
Resumen : Background Hereditary Hemorrhagic Telangiectasia (HHT) is a rare autosomal dominant vascular dysplasia, characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs). Despite an estimated global prevalence of 1 in 5,000, HHT remains underdiagnosed in many regions. Prior to this study, no epidemiologic data were available for Uruguay. Objective To describe the epidemiologic and clinical characteristics of HHT patients in Uruguay, estimate the national prevalence of the disease, assess adherence to international screening guidelines, and diagnostic delays. Methods A cross-sectional observational study was conducted in Uruguay using data from the national HHT reference registry. Patients who met the Curaçao criteria or had a confirmed pathogenic genetic variant were included. Data were obtained through a standardized telephone survey and medical record review. Variables included demographic data, clinical manifestations, diagnostic workup, and treatment. Descriptive and bivariate analyses were performed using SPSS software. Results The registry included 134 patients, of whom 90 were surveyed. Estimated HHT prevalence in Uruguay was 3.83 per 100,000 inhabitants (95% CI, 3.26 - 4.61). The mean age was 48.2 years (SD ± 18.3), with a female-to-male ratio of 1.73:1. Epistaxis affected 88.9% of adults, with more than 50% classified as moderate-to-severe and had anemia. Common treatments included oral (60.7%) and intravenous (41.6%) iron, tranexamic acid (24.7%), and propranolol (11.2%). Pulmonary, cerebral, hepatic and digestive arteriovenous malformations were present in 20%, 15%,19% and 50% of patients, respectively. The mean diagnostic delay was 5.7 years (SD ± 10.6). Only 22% of patients completed the recommended screening. Conclusion HHT remains underdiagnosed and undertreated in Uruguay, with significant diagnostic delays and low adherence to international screening guidelines. This first national epidemiological study underscores the urgent need for a formally recognized national referral center to ensure high-quality, multidisciplinary care and to raise disease awareness, with the aim of reducing preventable complications.
URI / Handle: https://hdl.handle.net/20.500.12381/5571
DOI: https://doi.org/10.1101/2025.08.18.25333772;
Institución responsable del proyecto: Metabolic Diseases and Aging Laboratory, Institut Pasteur de Montevideo. Mataojo 2020, Montevideo, Uruguay.
Unidad Académica Médica 1, Hospital Maciel. 25 de Mayo 174, Montevideo, Uruguay.
Facultad de Medicina, Universidad de la República Oriental del Uruguay.
Departamento de Medicina Transfusional, Centro Hospitalario Pereira Rossell. Lord Ponsonby 2410, Montevideo, Uruguay.
Financiadores: Programa de Desarrollo de la Ciencia Básica
Agencia Nacional de Investigación e Innovación, Fondo María Viñas
Brain Vascular Malformation Consortium
Identificador ANII: FMV_1_2021_1_166595
Nivel de Acceso: Acceso abierto
Licencia CC: Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND)
Aparece en las colecciones: Institut Pasteur de Montevideo

Archivos en este ítem:
archivo  Descripción Tamaño Formato
2025.08.18.25333772v1.full.pdfDescargar Criscuolo et al. preprint310.48 kBAdobe PDF

Las obras en REDI están protegidas por licencias Creative Commons.
Por más información sobre los términos de esta publicación, visita: Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND)